Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Breast Cancer

  Free Subscription


04.12.2017

3 Am J Surg
10 Anticancer Res
3 BMC Cancer
1 BMJ
3 Breast Cancer
1 Breast Cancer Res
12 Breast Cancer Res Treat
1 Breast J
1 Cancer Cell
1 Cancer Lett
5 Cancer Res
1 Cell
4 Clin Breast Cancer
2 Clin Cancer Res
4 Eur J Cancer
2 Eur J Surg Oncol
1 Exp Cell Res
1 Genes Chromosomes Cancer
3 Int J Cancer
1 Int J Radiat Oncol Biol Phys
1 J Biol Chem
1 J Natl Cancer Inst
1 J Surg Oncol
1 JAMA
1 Lancet Oncol
1 Oncology (Williston Park)
1 PLoS Comput Biol
7 PLoS One
1 Radiology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Surg

  1. HEELAN GLADDEN AA, Sams S, Gleisner A, Finlayson C, et al
    Re-excision rates after breast conserving surgery following the 2014 SSO-ASTRO guidelines.
    Am J Surg. 2017;214:1104-1109.
    PubMed     Text format     Abstract available

  2. VELAZCO CS, Wasif N, Pockaj BA, Gray RJ, et al
    Radioactive seed localization for breast conservation surgery: Low positive margin rate with no learning curve.
    Am J Surg. 2017;214:1091-1093.
    PubMed     Text format     Abstract available

  3. CHANG JM, Kosiorek HE, Wasif N, Gray RJ, et al
    The success of sentinel lymph node biopsy after neoadjuvant therapy: A single institution review.
    Am J Surg. 2017;214:1096-1101.
    PubMed     Text format     Abstract available


    Anticancer Res

  4. PEREIRA MC, Mohammed R, VAN Otterlo WAL, DE Koning CB, et al
    Evaluation of the Effects of Aminonaphthoquinone Derivatives in Combination with Curcumin Against ER-positive Breast Cancer and Related Tumours.
    Anticancer Res. 2017;37:6749-6759.
    PubMed     Text format     Abstract available

  5. SPARTALIS E, Tsilimigras DI, Charalampoudis P, Karachaliou GS, et al
    The "Yin and Yang" of Platelet-rich Plasma in Breast Reconstruction After Mastectomy or Lumpectomy for Breast Cancer.
    Anticancer Res. 2017;37:6557-6562.
    PubMed     Text format     Abstract available

  6. KAR A, Liu B, Gutierrez-Hartmann A
    ESE-1 Knockdown Attenuates Growth in Trastuzumab-resistant HER2(+) Breast Cancer Cells.
    Anticancer Res. 2017;37:6583-6591.
    PubMed     Text format     Abstract available

  7. MATSUI C, Takatani-Nakase T, Maeda S, Nakase I, et al
    Potential Roles of GLUT12 for Glucose Sensing and Cellular Migration in MCF-7 Human Breast Cancer Cells Under High Glucose Conditions.
    Anticancer Res. 2017;37:6715-6722.
    PubMed     Text format     Abstract available

  8. STOPE MB, Weiss M, Koensgen D, Popp SL, et al
    Y-box Binding Protein-1 Enhances Oncogenic Transforming Growth Factor beta Signaling in Breast Cancer Cells via Triggering Phospho-Activation of Smad2.
    Anticancer Res. 2017;37:6745-6748.
    PubMed     Text format     Abstract available

  9. AULA H, Skytta T, Tuohinen S, Luukkaala T, et al
    Adjuvant Breast Cancer Treatments Induce Changes in Homoarginine Level - A Prospective Observational Study.
    Anticancer Res. 2017;37:6815-6824.
    PubMed     Text format     Abstract available

  10. NIMEUS E, Folkesson E, Nodin B, Hartman L, et al
    Androgen Receptor in Stage I-II Primary Breast Cancer -Prognostic Value and Distribution in Subgroups.
    Anticancer Res. 2017;37:6845-6853.
    PubMed     Text format     Abstract available

  11. MOKBEL K, Wazir U, El Hage Chehade H, Manson A, et al
    A Comparison of the Performance of EndoPredict Clinical and NHS PREDICT in 120 Patients Treated for ER-positive Breast Cancer.
    Anticancer Res. 2017;37:6863-6869.
    PubMed     Text format     Abstract available

  12. YAMANOUCHI K, Kuba S, Sakimura C, Morita M, et al
    The Relationship Between Peripheral Neuropathy Induced by Docetaxel and Systemic Inflammation-based Parameters in Patients with Breast Cancer.
    Anticancer Res. 2017;37:6947-6951.
    PubMed     Text format     Abstract available

  13. PESSINA F, Navarria P, Cozzi L, Franceschini D, et al
    Outcome Evaluation of HER2 Breast Cancer Patients with Limited Brain Metastasis.
    Anticancer Res. 2017;37:7057-7062.
    PubMed     Text format     Abstract available


    BMC Cancer

  14. SENGAL AT, Haj-Mukhtar NS, Elhaj AM, Bedri S, et al
    Immunohistochemistry defined subtypes of breast cancer in 678 Sudanese and Eritrean women; hospitals based case series.
    BMC Cancer. 2017;17:804.
    PubMed     Text format     Abstract available

  15. KARTHIK GM, Rantalainen M, Stalhammar G, Lovrot J, et al
    Intra-tumor heterogeneity in breast cancer has limited impact on transcriptomic-based molecular profiling.
    BMC Cancer. 2017;17:802.
    PubMed     Text format     Abstract available

  16. QATTAN A, Intabli H, Alkhayal W, Eltabache C, et al
    Robust expression of tumor suppressor miRNA's let-7 and miR-195 detected in plasma of Saudi female breast cancer patients.
    BMC Cancer. 2017;17:799.
    PubMed     Text format     Abstract available


    BMJ

  17. ROBERTSON E
    Patient commentary: the current model has failed.
    BMJ. 2017;359:j4568.
    PubMed     Text format    


    Breast Cancer

  18. INOUE H, Horii R, Ito Y, Iwase T, et al
    Tumor-infiltrating lymphocytes affect the efficacy of trastuzumab-based treatment in human epidermal growth factor receptor 2-positive breast cancer.
    Breast Cancer. 2017 Nov 28. pii: 10.1007/s12282-017-0822.
    PubMed     Text format     Abstract available

  19. ZHAO Q, Song W, He DY, Li Y, et al
    Identification of key gene modules and pathways of human breast cancer by co-expression analysis.
    Breast Cancer. 2017 Nov 23. pii: 10.1007/s12282-017-0817.
    PubMed     Text format     Abstract available

  20. ZHANG ZL, Jiang QC, Wang SR
    Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation.
    Breast Cancer. 2017 Nov 27. pii: 10.1007/s12282-017-0821.
    PubMed     Text format     Abstract available


    Breast Cancer Res

  21. HELLAND T, Henne N, Bifulco E, Naume B, et al
    Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients.
    Breast Cancer Res. 2017;19:125.
    PubMed     Text format     Abstract available


    Breast Cancer Res Treat

  22. TRENTHAM-DIETZ A, Ergun MA, Alagoz O, Stout NK, et al
    Comparative effectiveness of incorporating a hypothetical DCIS prognostic marker into breast cancer screening.
    Breast Cancer Res Treat. 2017 Nov 28. pii: 10.1007/s10549-017-4582.
    PubMed     Text format     Abstract available

  23. REINERT T, Debiasi M, Bines J, Barrios CH, et al
    Trends in progression-free survival (PFS) and time to progression (TTP) over time within first-line aromatase inhibitors trials in hormone receptor-positive advanced breast cancer.
    Breast Cancer Res Treat. 2017 Nov 30. pii: 10.1007/s10549-017-4593.
    PubMed     Text format     Abstract available

  24. XIA Z, Baumgartner KB, Baumgartner RN, Boone SD, et al
    Associations between ALDH1A1 polymorphisms, alcohol consumption, and mortality among Hispanic and non-Hispanic white women diagnosed with breast cancer: the Breast Cancer Health Disparities Study.
    Breast Cancer Res Treat. 2017 Nov 30. pii: 10.1007/s10549-017-4600.
    PubMed     Text format     Abstract available

  25. ALTUNDAG K
    Does tacrolimus have any positive impact on outcome of post-transplant breast cancer patients?
    Breast Cancer Res Treat. 2017 Nov 24. pii: 10.1007/s10549-017-4589.
    PubMed     Text format    

  26. MATIKAS A, Margolin S, Hellstrom M, Johansson H, et al
    Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer.
    Breast Cancer Res Treat. 2017 Nov 30. pii: 10.1007/s10549-017-4599.
    PubMed     Text format     Abstract available

  27. COLOMER R, Hall P, Szkultecka-Debek M, Bondi RC, et al
    Real-world treatment in patients with HER2+ metastatic breast cancer : Treatment decisions in HER2+ mBC.
    Breast Cancer Res Treat. 2017 Nov 23. pii: 10.1007/s10549-017-4567.
    PubMed     Text format     Abstract available

  28. WANG Z, Kong J, Wu Y, Zhang J, et al
    PRMT5 determines the sensitivity to chemotherapeutics by governing stemness in breast cancer.
    Breast Cancer Res Treat. 2017 Nov 28. pii: 10.1007/s10549-017-4597.
    PubMed     Text format     Abstract available

  29. PEZO RC, Chen TW, Berman HK, Mulligan AM, et al
    Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer.
    Breast Cancer Res Treat. 2017 Nov 24. pii: 10.1007/s10549-017-4580.
    PubMed     Text format     Abstract available

  30. LIU YL, Connolly EP, Kalinsky K
    Obesity's impact on survival is independent of dose adjustments in neoadjuvant chemotherapy in women with breast cancer.
    Breast Cancer Res Treat. 2017 Nov 24. pii: 10.1007/s10549-017-4590.
    PubMed     Text format    

  31. VILLEGAS SL, Darb-Esfahani S, von Minckwitz G, Huober J, et al
    Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer.
    Breast Cancer Res Treat. 2017 Nov 25. pii: 10.1007/s10549-017-4581.
    PubMed     Text format     Abstract available

  32. LOHRISCH C, Francl M, Sun S, Villa D, et al
    Willingness of breast cancer patients to undergo biopsy and breast cancer clinicians' practices around seeking biopsy at the time of breast cancer relapse.
    Breast Cancer Res Treat. 2017 Nov 27. pii: 10.1007/s10549-017-4586.
    PubMed     Text format     Abstract available

  33. YU YF, Wang Y, Fu TP, Chen K, et al
    Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer.
    Breast Cancer Res Treat. 2017 Nov 29. pii: 10.1007/s10549-017-4592.
    PubMed     Text format     Abstract available


    Breast J

  34. LI T, Tang L, Gandomkar Z, Heard R, et al
    Mammographic density and other risk factors for breast cancer among women in China.
    Breast J. 2017 Nov 29. doi: 10.1111/tbj.12967.
    PubMed     Text format    


    Cancer Cell

  35. PALAZON A, Tyrakis PA, Macias D, Velica P, et al
    An HIF-1alpha/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression.
    Cancer Cell. 2017;32:669-683.
    PubMed     Text format     Abstract available


    Cancer Lett

  36. CAI X, Wang X, Cao C, Gao Y, et al
    HBXIP-elevated methyltransferase METTL3 promotes the progression of breast cancer via inhibiting tumor suppressor let-7g.
    Cancer Lett. 2017 Nov 21. pii: S0304-3835(17)30740.
    PubMed     Text format     Abstract available


    Cancer Res

  37. CAREY JP, Karakas C, Bui T, Chen X, et al
    Synthetic lethality of PARP inhibitors in combination with MYC blockade is independent of BRCA status in triple negative breast cancer.
    Cancer Res. 2017 Nov 27. pii: 0008-5472.CAN-17-1494.
    PubMed     Text format     Abstract available

  38. PAJIC M, Froio D, Daly S, Doculara L, et al
    miR-139-5p modulates radiotherapy resistance in breast cancer by repressing multiple gene networks of DNA repair and ROS defense.
    Cancer Res. 2017 Nov 27. pii: 0008-5472.CAN-16-3105.
    PubMed     Text format     Abstract available

  39. BYRD TT, Fousek K, Pignata A, Szot C, et al
    TEM8/ANTXR1-specific CAR T cells as a targeted therapy for triple-negative breast cancer.
    Cancer Res. 2017 Nov 28. pii: 0008-5472.CAN-16-1911.
    PubMed     Text format     Abstract available

  40. HOU P, Li L, Chen F, Chen Y, et al
    PTBP3-mediated regulation of ZEB1 mRNA stability promotes epithelial-mesenchymal transition in breast cancer.
    Cancer Res. 2017 Nov 29. pii: 0008-5472.CAN-17-0883.
    PubMed     Text format     Abstract available

  41. CAMPBELL TM, Castro MA, deOliveira KG, Ponder BA, et al
    ER alpha binding by transcription factors NFIB and YBX1 enables FGFR2 signalling to modulate estrogen responsiveness in breast cancer.
    Cancer Res. 2017 Nov 27. pii: 0008-5472.CAN-17-1153.
    PubMed     Text format     Abstract available


    Cell

  42. YU W, Goncalves KA, Li S, Kishikawa H, et al
    Plexin-B2 Mediates Physiologic and Pathologic Functions of Angiogenin.
    Cell. 2017;171:849-864.
    PubMed     Text format     Abstract available


    Clin Breast Cancer

  43. MCVEIGH TP, Wiggins J, Ward S, Kemp Z, et al
    Successful Repatriation of Breast Cancer Surveillance for High-Risk Women to the UK National Health Service Breast Screening Programme.
    Clin Breast Cancer. 2017 Oct 28. pii: S1526-8209(17)30489.
    PubMed     Text format     Abstract available

  44. KARAKAS Y, Dizdar O, Aksoy S, Hayran M, et al
    The Effect of Total Size of Lesions in Multifocal/Multicentric Breast Cancer on Survival.
    Clin Breast Cancer. 2017 Nov 9. pii: S1526-8209(17)30449.
    PubMed     Text format     Abstract available

  45. CHANG AE, Wu QV, Jenkins IC, Specht JM, et al
    Phase I/II Trial of Combined Pegylated Liposomal Doxorubicin and Cyclophosphamide in Metastatic Breast Cancer.
    Clin Breast Cancer. 2017 Oct 9. pii: S1526-8209(17)30280.
    PubMed     Text format     Abstract available

  46. FISCHER A, Ziogas A, Anton-Culver H
    Negative Valence Life Events Promote Breast Cancer Development.
    Clin Breast Cancer. 2017 Nov 1. pii: S1526-8209(16)30501.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  47. LENZ G, Hamilton A, Geng S, Hong T, et al
    t-Darpp activates IGF-1R signaling to regulate glucose metabolism in trastuzumab-resistant breast cancer cells.
    Clin Cancer Res. 2017 Nov 27. pii: 1078-0432.CCR-17-0824.
    PubMed     Text format     Abstract available

  48. ROSSI G, Mu Z, Rademaker A, Austin L, et al
    Cell-Free DNA and Circulating Tumor Cells: Comprehensive liquid biopsy analysis in Advanced Breast Cancer.
    Clin Cancer Res. 2017 Nov 27. pii: 1078-0432.CCR-17-2092.
    PubMed     Text format     Abstract available


    Eur J Cancer

  49. MARTIN TA, Watkins G, Mansel RE, Jiang WG, et al
    Corrigendum to "Loss of tight junction plaque molecules in breast cancer tissues is associated with a poor prognosis in patients with breast cancer" [Eur J Cancer 40 (18) (2004) 2717-2725].
    Eur J Cancer. 2017 Nov 23. pii: S0959-8049(17)31384.
    PubMed     Text format    

  50. DUFFY SW, Morrish OWE, Allgood PC, Black R, et al
    Mammographic density and breast cancer risk in breast screening assessment cases and women with a family history of breast cancer.
    Eur J Cancer. 2017;88:48-56.
    PubMed     Text format     Abstract available

  51. MUSOLINO A, Falcini F, Sikokis A, Boggiani D, et al
    Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study.
    Eur J Cancer. 2017;88:10-20.
    PubMed     Text format     Abstract available

  52. MILES D, Cameron D, Hilton M, Garcia J, et al
    Overall survival in MERiDiAN, a double-blind placebo-controlled randomised phase III trial evaluating first-line bevacizumab plus paclitaxel for HER2-negative metastatic breast cancer.
    Eur J Cancer. 2017 Nov 23. pii: S0959-8049(17)31358.
    PubMed     Text format    


    Eur J Surg Oncol

  53. CHARALAMPOUDIS P, Markopoulos C, Kovacs T
    Controversies and recommendations regarding sentinel lymph node biopsy in primary breast cancer: A comprehensive review of current data.
    Eur J Surg Oncol. 2017 Nov 13. pii: S0748-7983(17)30955.
    PubMed     Text format     Abstract available

  54. BUNDRED NJ
    Erratum to "Impact of Oncotype DX Breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: Real world experience in Greater Manchester, UK" [Eur J Surg Oncol 43 (5) (2017) 931-937].
    Eur J Surg Oncol. 2017 Nov 23. pii: S0748-7983(17)30539.
    PubMed     Text format    


    Exp Cell Res

  55. LO JH, Chen TT
    Production of bioactive recombinant human Eb-peptide of pro-IGF-I and identification of binding components from the plasma membrane of human breast cancer cells (MDA-MB-231).
    Exp Cell Res. 2017 Nov 27. pii: S0014-4827(17)30628.
    PubMed     Text format     Abstract available


    Genes Chromosomes Cancer

  56. OLTMANN J, Heselmeyer-Haddad K, Hernandez LS, Meyer R, et al
    Aneuploidy, TP53 mutation, and amplification of MYC correlate with increased intratumor heterogeneity and poor prognosis of breast cancer patients.
    Genes Chromosomes Cancer. 2017 Nov 27. doi: 10.1002/gcc.22515.
    PubMed     Text format     Abstract available


    Int J Cancer

  57. BASU P, Ponti A, Anttila A, Ronco G, et al
    Status of implementation and organization of cancer screening in The European Union Member States-Summary results from the second European screening report.
    Int J Cancer. 2018;142:44-56.
    PubMed     Text format     Abstract available

  58. LEE KR, Hwang IC, Do Han K, Jung J, et al
    Waist circumference and risk of breast cancer in Korean women: A nationwide cohort study.
    Int J Cancer. 2017 Nov 29. doi: 10.1002/ijc.31180.
    PubMed     Text format     Abstract available

  59. HIS M, Le Guelennec M, Mesrine S, Boutron-Ruault MC, et al
    Life course evolution of body size and breast cancer survival in the E3N cohort.
    Int J Cancer. 2017 Nov 27. doi: 10.1002/ijc.31177.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  60. PIERCE LJ, Feng M, Griffith KA, Jagsi R, et al
    Recent Time Trends and Predictors of Heart Dose From Breast Radiation Therapy in a Large Quality Consortium of Radiation Oncology Practices.
    Int J Radiat Oncol Biol Phys. 2017;99:1154-1161.
    PubMed     Text format     Abstract available


    J Biol Chem

  61. NADANAKA S, Kinouchi H, Kitagawa H
    Chondroitin sulfates-mediated N-cadherin/beta-catenin signaling is associated with basal-like breast cancer cell invasion.
    J Biol Chem. 2017 Nov 28. pii: M117.814509. doi: 10.1074/jbc.M117.814509.
    PubMed     Text format     Abstract available


    J Natl Cancer Inst

  62. BELKACEMI Y, Kuten A
    RE: Regional Nodal Irradiation After Breast-Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial.
    J Natl Cancer Inst. 2017 Nov 21. pii: 4645256. doi: 10.1093.
    PubMed     Text format    


    J Surg Oncol

  63. TATARA T, Mukohara T, Shimono Y, Yamasaki T, et al
    Expression of programmed death-1 in sentinel lymph nodes of breast cancer.
    J Surg Oncol. 2017 Nov 28. doi: 10.1002/jso.24937.
    PubMed     Text format     Abstract available


    JAMA

  64. THOMAS R, Fysh ETH, Smith NA, Lee P, et al
    Effect of an Indwelling Pleural Catheter vs Talc Pleurodesis on Hospitalization Days in Patients With Malignant Pleural Effusion: The AMPLE Randomized Clinical Trial.
    JAMA. 2017;318:1903-1912.
    PubMed     Text format     Abstract available


    Lancet Oncol

  65. HURVITZ SA, Martin M, Symmans WF, Jung KH, et al
    Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
    Lancet Oncol. 2017 Nov 23. pii: S1470-2045(17)30716.
    PubMed     Text format     Abstract available


    Oncology (Williston Park)

  66. GARBER J
    Judy Garber on PARP Inhibitors for Triple-Negative Breast Cancer.
    Oncology (Williston Park). 2017;31:814-5.
    PubMed     Text format    


    PLoS Comput Biol

  67. PATKAR S, Magen A, Sharan R, Hannenhalli S, et al
    A network diffusion approach to inferring sample-specific function reveals functional changes associated with breast cancer.
    PLoS Comput Biol. 2017;13:e1005793.
    PubMed     Text format     Abstract available


    PLoS One

  68. THOMPSON KJ, Ingle JN, Tang X, Chia N, et al
    A comprehensive analysis of breast cancer microbiota and host gene expression.
    PLoS One. 2017;12:e0188873.
    PubMed     Text format     Abstract available

  69. MARINHO EDC, Custodio IDD, Ferreira IB, Crispim CA, et al
    Impact of chemotherapy on perceptions related to food intake in women with breast cancer: A prospective study.
    PLoS One. 2017;12:e0187573.
    PubMed     Text format     Abstract available

  70. AZIZI M, Ghourchian H, Yazdian F, Dashtestani F, et al
    Cytotoxic effect of albumin coated copper nanoparticle on human breast cancer cells of MDA-MB 231.
    PLoS One. 2017;12:e0188639.
    PubMed     Text format     Abstract available

  71. MAYORAL-VARO V, Calcabrini A, Sanchez-Bailon MP, Martin-Perez J, et al
    miR205 inhibits stem cell renewal in SUM159PT breast cancer cells.
    PLoS One. 2017;12:e0188637.
    PubMed     Text format     Abstract available

  72. ARENAS M, Garcia-Heredia A, Cabre N, Luciano-Mateo F, et al
    Effect of radiotherapy on activity and concentration of serum paraoxonase-1 in breast cancer patients.
    PLoS One. 2017;12:e0188633.
    PubMed     Text format     Abstract available

  73. AHN SG, Bae SJ, Yoon C, Cha YJ, et al
    Chemosensitivity to doxorubicin of ER-positive/HER2-negative breast cancers with high 21-gene recurrence score: A study based on in vitro chemoresponse assay.
    PLoS One. 2017;12:e0187679.
    PubMed     Text format     Abstract available

  74. ZEUNE L, van Dalum G, Decraene C, Proudhon C, et al
    Quantifying HER-2 expression on circulating tumor cells by ACCEPT.
    PLoS One. 2017;12:e0186562.
    PubMed     Text format     Abstract available


    Radiology

  75. LUO J, Johnston BS, Kitsch AE, Hippe DS, et al
    Ductal Carcinoma in Situ: Quantitative Preoperative Breast MR Imaging Features Associated with Recurrence after Treatment.
    Radiology. 2017 Sep 14:170587. doi: 10.1148/radiol.2017170587.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: